ACURX PHARMACEUTICALS, INC. ANNUAL MEETING OF STOCKHOLDERS - ACURX PHARMACEUTICALS INC

Financial Performance:

• No financial results, revenue figures, earnings, profit margins, cash flow, debt levels, or specific industry-relevant financial metrics were disclosed; the transcript contains no discussion of fiscal year performance or balance sheet details.

Guidance and Future Outlook:

• No forward-looking guidance, growth projections, long-term strategic goals, or market trend analysis regarding future operations were provided; the meeting was strictly procedural.

Business Segments and Product Lines:

• No updates on product launches, new customer agreements, or segment-specific performance were mentioned; the agenda did not include operational reviews.

Market and Competitive Landscape:

• No information regarding market share, competitive positioning, or industry trends was discussed; the call was limited to corporate governance matters.

Risks and Challenges:

• Management referenced standard risks outlined in recent 10-K and 10-Q filings and noted that the meeting is not a forum for disclosing material nonpublic information (Regulation FD).
• No specific new operational, regulatory, or market risks were detailed beyond the standard forward-looking statement warnings.

Management Commentary and Tone:

• Management tone was formal, procedural, and neutral, consistent with a corporate annual meeting focused on voting and compliance.
• Executive Chairman Bob DeLucia and CEO Dave Lucci led the meeting but did not offer substantive commentary on business strategy or results.
• Management stated they would provide general background but refused to provide material nonpublic information.

Analyst Questions and Answers:

• No analyst questions were asked or answered during the session; CFO Rob Schauer confirmed there were no questions in the queue on the web portal.
• The Q&A portion was effectively non-existent due to the lack of stockholder inquiries.

Other Key Points:

• The primary purpose of the meeting was to vote on two proposals: (1) electing Class II directors David Lucci and Dr. Jack Dean to three-year terms expiring in 2029, and (2) ratifying Kohn Resnick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• A quorum was established with 2,890,899 shares present (approx. 52.8% of outstanding stock).
• Election results: David Lucci (1,187,323 votes for, 73,804 withheld) and Dr. Jack Dean (1,203,310 votes for, 57,817 withheld) were elected.
• Accounting firm ratification: Approved by 2,877,193 votes for, 8,473 against, and 5,233 abstained.
• The meeting was held virtually on October 1, 2026 (implied by the 10 a.m. Eastern Time start and context of 2026 annual meeting), with no other business transacted.